Ultragenyx Pharmaceutical | RARE - Trade Debtors


Ultragenyx Pharmaceutical reported $60M in Trade Debtors for its fiscal quarter ending in March of 2026.





Trade Debtors Change Date
Acadia Pharmaceuticals USD 166.33M 17.95M Jun/2026
Agios Pharmaceuticals USD 16.13M 5.56M Mar/2026
Alnylam Pharmaceuticals USD 912.74M 28.78M Jun/2026
BioCryst Pharmaceuticals USD 110.76M 3.94M Jun/2026
BioMarin Pharmaceutical USD 1.06B 157.13M Jun/2026
Immunic USD 333K 156K Dec/2025
Insmed USD 215.32M 36.77M Jun/2026
Ionis Pharmaceuticals USD 58.84M 15.16M Jun/2026
Karyopharm Therapeutics USD 23.36M 2.82M Mar/2026
Kyowa Hakko Kirin JPY 153.3B 32.4B Jun/2026
MacroGenics USD 10.42M 2.95M Mar/2026
Moderna USD 17M 54M Jun/2026
Neurocrine Biosciences USD 887M 118.9M Jun/2026
PTC Therapeutics USD 219.92M 38.3M Mar/2026
Puma Biotechnology USD 28.1M 3.52M Jun/2024
Regeneron Pharmaceuticals USD 6.57B 834.4M Jun/2026
Sarepta Therapeutics USD 393.8M 154.11M Jun/2026
Ultragenyx Pharmaceutical USD 60M 98M Mar/2026
Vertex Pharmaceuticals USD 2.13B 138.2M Jun/2026